Product Code: GVR-1-68038-427-7
Pen Needles Market Growth & Trends
The global pen needles market size is expected to reach a value of USD 7.7 billion by 2030, expanding at a CAGR of 11.8%, according to a new report by Grand View Research, Inc. Rising prevalence of diabetes is the primary reason for the significant growth of the pen needles market. According to the National Library of Medicine, the number of people with diabetes is expected to climb by 1.51 million in 2023, owing primarily to the ageing population. Such high prevalence of diabetes across the globe has led to rising demand for pen needles. Patients suffering from diabetes commonly use injectable pen devices, which help in easy drug delivery.
In addition, obesity is a significant cause of diabetes. Obese people often suffer from type 2 diabetes, which makes them one of the highest revenue contributors to the target market. Thus, people with type 2 diabetes are the common target population for companies manufacturing pen needles.
Rising technological advancements is also expected to drive the market growth. Pen needles allow comfort and easy mode of insulin delivery. These devices are technologically advanced and provide a superior alternative drug delivery method in comparison to syringes and vials. For instance, Becton, Dickinson, and Company launched BD Ultra-Fine Nano 4mm Pen Needles with Easy Flow Technology, which will enable diabetic patients with easy adherence to insulin therapy regimens.
Pen Needles Market Report Highlights
- Standard needles dominated the market in 2022 due to the availability of cost-effective needles as compared to safety needles
- Safety pen needles are anticipated to showcase lucrative growth over the forecast period due to the continuous technological advancements
- Amongst the needle lengths, 8mm held the largest share in 2022. This is due to the convenience offered by this needle type on diabetic patients
- Needle length of 4mm are expected to witness attractive CAGR over the forecast period owing to its short length
- Insulin therapy accounted for the largest market share in 2022 due to rising awareness regarding self-administration of insulin amongst the diabetic patients
- Europe dominated the pen needles market in 2022 followed by North America owing to the high prevalence of diabetes in the European region
- Asia Pacific region is anticipated to exhibit the highest growth rate over the forecast period owing to the rising awareness levels amongst the diabetic population regarding easy drug delivery
- Some of the key players include Becton, Dickinson and Company, B. Braun Melsungen AG, Novo Nordisk A/S, Owen Mumford, Ltd., Ypsomed, HTL-STREFA, and TERUMO CORPORATION.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Product
- 1.1.2. Needle Length
- 1.1.3. Therapy
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.3.5.1. Data for primary interviews in North America
- 1.3.5.2. Data for primary interviews in Europe
- 1.3.5.3. Data for primary interviews in Asia Pacific
- 1.3.5.4. Data for primary interviews in Latin America
- 1.3.5.5. Data for Primary interviews in MEA
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.6.1. Commodity flow analysis (Model 1)
- 1.6.1.1. Approach 1: Commodity flow approach
- 1.6.2. Volume price analysis (Model 2)
- 1.6.2.1. Approach 2: Volume price analysis
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Snapshot
Chapter 3. Pen Needles Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Industry Value Chain Analysis
- 3.3.1. Reimbursement framework
- 3.4. Market Dynamics
- 3.4.1. Market driver analysis
- 3.4.1.1. Growing prevalence of diabetes
- 3.4.1.2. Technological advancements
- 3.4.2. Market restraint analysis
- 3.4.2.1. Preference for alternative drug delivery method
- 3.4.2.2. Lack of skilled professionals
- 3.5. Pen Needles Market Analysis Tools
- 3.5.1. Industry Analysis - Porter's
- 3.5.1.1. Supplier power
- 3.5.1.2. Buyer power
- 3.5.1.3. Substitution threat
- 3.5.1.4. Threat of new entrant
- 3.5.1.5. Competitive rivalry
- 3.5.2. PESTEL Analysis
- 3.5.2.1. Political landscape
- 3.5.2.2. Technological landscape
- 3.5.2.3. Economic landscape
- 3.5.3. Major Deals & Strategic Alliances Analysis
- 3.5.4. Market Entry Strategies
Chapter 4. Pen Needles Market: Product Estimates & Trend Analysis
- 4.1. Definitions and Scope
- 4.1.1. Standard Pen Needles
- 4.1.2. Safety Pen Needles
- 4.2. Product Market Share, 2022 & 2030
- 4.3. Segment Dashboard
- 4.4. Global Pen Needles Market by Product Outlook
- 4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.5.1. Standard Pen Needles
- 4.5.1.1. Standard pen needles market estimates and forecast 2018 to 2030 (USD Million)
- 4.5.2. Safety Pen Needles
- 4.5.2.1. Safety pen needles market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Pen Needles Market: Needle Length Estimates & Trend Analysis
- 5.1. Definitions and Scope
- 5.1.1. 4mm
- 5.1.2. 5mm
- 5.1.3. 6mm
- 5.1.4. 8mm
- 5.1.5. 10mm
- 5.1.6. 12mm
- 5.2. Needle Length Market Share, 2022 & 2030
- 5.3. Segment Dashboard
- 5.4. Pen Needles Market by Needle Length Outlook
- 5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.5.1. 4mm
- 5.5.1.1. 4mm market estimates and forecast 2018 to 2030 (USD Million)
- 5.5.2. 5mm
- 5.5.2.1. 5mm market estimates and forecast 2018 to 2030 (USD Million)
- 5.5.3. 6mm
- 5.5.3.1. 6mm market estimates and forecast 2018 to 2030 (USD Million)
- 5.5.4. 8mm
- 5.5.4.1. 8mm market estimates and forecast 2018 to 2030 (USD Million)
- 5.5.5. 10mm
- 5.5.5.1. 10mm market estimates and forecast 2018 to 2030 (USD Million)
- 5.5.6. 12mm
- 5.5.6.1. 12mm market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Pen Needles Market: Therapy Estimates & Trend Analysis
- 6.1. Definitions and Scope
- 6.1.1. Insulin
- 6.1.2. Glucagon-like-peptide-1
- 6.1.3. Growth Harmone
- 6.2. Therapy Market Share, 2022 & 2030
- 6.3. Segment Dashboard
- 6.4. Pen Needles Market by Therapy Outlook
- 6.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.5.1. Insulin
- 6.5.1.1. Insulin market estimates and forecast 2018 to 2030 (USD Million)
- 6.5.2. Glucagon-like-peptide-1
- 6.5.2.1. Glucagon-like-peptide-1 market estimates and forecast 2018 to 2030 (USD Million)
- 6.5.3. Growth Harmone
- 6.5.3.1. Growth harmone market estimates and forecast 2018 to 2030 (USD Million)
Chapter 7. Pen Needles Market: Regional Estimates & Trend Analysis
- 7.1. Regional market share analysis, 2022 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Global Regional Market Snapshot
- 7.4. Regional Market Share and Leading Players, 2022
- 7.4.1. North America
- 7.4.2. Europe
- 7.4.3. Asia Pacific
- 7.4.4. Latin America
- 7.4.5. Middle East and Africa
- 7.5. Market Application, & Forecasts and Trend Analysis, 2018 to 2030:
- 7.6. North America
- 7.6.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
- 7.6.2. U.S.
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Competitive Scenario
- 7.6.2.3. Regulatory framework
- 7.6.2.4. Reimbursement scenario
- 7.6.2.5. U.S. market estimates and forecasts, 2018 - 2030
- 7.6.3. Canada
- 7.6.3.1. Key country dynamics
- 7.6.3.2. Competitive Scenario
- 7.6.3.3. Regulatory framework
- 7.6.3.4. Reimbursement scenario
- 7.6.3.5. Canada market estimates and forecasts, 2018 - 2030
- 7.7. Europe
- 7.7.1. UK
- 7.7.1.1. Key country dynamics
- 7.7.1.2. Competitive Scenario
- 7.7.1.3. Regulatory framework
- 7.7.1.4. Reimbursement scenario
- 7.7.1.5. UK market estimates and forecasts, 2018 - 2030
- 7.7.2. Germany
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Competitive Scenario
- 7.7.2.3. Regulatory framework
- 7.7.2.4. Reimbursement scenario
- 7.7.2.5. Germany market estimates and forecasts, 2018 - 2030
- 7.7.3. France
- 7.7.3.1. Key country dynamics
- 7.7.3.2. Competitive Scenario
- 7.7.3.3. Regulatory framework
- 7.7.3.4. Reimbursement scenario
- 7.7.3.5. France market estimates and forecasts, 2018 - 2030
- 7.7.4. Italy
- 7.7.4.1. Key country dynamics
- 7.7.4.2. Competitive Scenario
- 7.7.4.3. Regulatory framework
- 7.7.4.4. Reimbursement scenario
- 7.7.4.5. Italy market estimates and forecasts, 2018 - 2030
- 7.7.5. Spain
- 7.7.5.1. Key country dynamics
- 7.7.5.2. Competitive Scenario
- 7.7.5.3. Regulatory framework
- 7.7.5.4. Reimbursement scenario
- 7.7.5.5. Spain market estimates and forecasts, 2018 - 2030
- 7.7.6. Denmark
- 7.7.6.1. Key country dynamics
- 7.7.6.2. Competitive Scenario
- 7.7.6.3. Regulatory framework
- 7.7.6.4. Reimbursement scenario
- 7.7.6.5. Denmark market estimates and forecasts, 2018 - 2030
- 7.7.7. Sweden
- 7.7.7.1. Key country dynamics
- 7.7.7.2. Competitive Scenario
- 7.7.7.3. Regulatory framework
- 7.7.7.4. Reimbursement scenario
- 7.7.7.5. Sweden market estimates and forecasts, 2018 - 2030
- 7.7.8. Norway
- 7.7.8.1. Key country dynamics
- 7.7.8.2. Competitive Scenario
- 7.7.8.3. Regulatory framework
- 7.7.8.4. Reimbursement scenario
- 7.7.8.5. Norway market estimates and forecasts, 2018 - 2030
- 7.8. Asia Pacific
- 7.8.1. Japan
- 7.8.1.1. Key country dynamics
- 7.8.1.2. Competitive Scenario
- 7.8.1.3. Regulatory framework
- 7.8.1.4. Reimbursement scenario
- 7.8.1.5. Japan market estimates and forecasts, 2018 - 2030
- 7.8.2. India
- 7.8.2.1. Key country dynamics
- 7.8.2.2. Competitive Scenario
- 7.8.2.3. Regulatory framework
- 7.8.2.4. Reimbursement scenario
- 7.8.2.5. India market estimates and forecasts, 2018 - 2030
- 7.8.3. China
- 7.8.3.1. Key country dynamics
- 7.8.3.2. Competitive Scenario
- 7.8.3.3. Regulatory framework
- 7.8.3.4. Reimbursement scenario
- 7.8.3.5. China market estimates and forecasts, 2018 - 2030
- 7.8.4. South Korea
- 7.8.4.1. Key country dynamics
- 7.8.4.2. Competitive Scenario
- 7.8.4.3. Regulatory framework
- 7.8.4.4. Reimbursement scenario
- 7.8.4.5. South Korea market estimates and forecasts, 2018 - 2030
- 7.8.5. Australia
- 7.8.5.1. Key country dynamics
- 7.8.5.2. Competitive Scenario
- 7.8.5.3. Regulatory framework
- 7.8.5.4. Reimbursement scenario
- 7.8.5.5. Australia market estimates and forecasts, 2018 - 2030
- 7.8.6. Thailand
- 7.8.6.1. Key country dynamics
- 7.8.6.2. Competitive Scenario
- 7.8.6.3. Regulatory framework
- 7.8.6.4. Reimbursement scenario
- 7.8.6.5. Thailand market estimates and forecasts, 2018 - 2030
- 7.9. Latin America
- 7.9.1. Brazil
- 7.9.1.1. Key country dynamics
- 7.9.1.2. Competitive Scenario
- 7.9.1.3. Regulatory framework
- 7.9.1.4. Reimbursement scenario
- 7.9.1.5. Brazil market estimates and forecasts, 2018 - 2030
- 7.9.2. Mexico
- 7.9.2.1. Key country dynamics
- 7.9.2.2. Competitive Scenario
- 7.9.2.3. Regulatory framework
- 7.9.2.4. Reimbursement scenario
- 7.9.2.5. Mexico market estimates and forecasts, 2018 - 2030
- 7.9.3. Argentina
- 7.9.3.1. Key country dynamics
- 7.9.3.2. Competitive Scenario
- 7.9.3.3. Regulatory framework
- 7.9.3.4. Reimbursement scenario
- 7.9.3.5. Argentina market estimates and forecasts, 2018 - 2030
- 7.10. MEA
- 7.10.1. South Africa
- 7.10.1.1. Key country dynamics
- 7.10.1.2. Competitive Scenario
- 7.10.1.3. Regulatory framework
- 7.10.1.4. Reimbursement scenario
- 7.10.1.5. South Africa market estimates and forecasts, 2018 - 2030
- 7.10.2. Saudi Arabia
- 7.10.2.1. Key country dynamics
- 7.10.2.2. Competitive Scenario
- 7.10.2.3. Regulatory framework
- 7.10.2.4. Reimbursement scenario
- 7.10.2.5. Saudi Arabia market estimates and forecasts, 2018 - 2030
- 7.10.3. UAE
- 7.10.3.1. Key country dynamics
- 7.10.3.2. Competitive Scenario
- 7.10.3.3. Regulatory framework
- 7.10.3.4. Reimbursement scenario
- 7.10.3.5. UAE market estimates and forecasts, 2018 - 2030
- 7.10.4. Kuwait
- 7.10.4.1. Key country dynamics
- 7.10.4.2. Competitive Scenario
- 7.10.4.3. Regulatory framework
- 7.10.4.4. Reimbursement scenario
- 7.10.4.5. Kuwait market estimates and forecasts, 2018 - 2030
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.3. Vendor Landscape
- 8.3.1. List of key distributors and channel partners
- 8.3.2. Key customers
- 8.3.3. Key company market share analysis, 2022
- 8.3.4. Novo Nordisk A/S
- 8.3.4.1. Company overview
- 8.3.4.2. Financial performance
- 8.3.4.3. Product benchmarking
- 8.3.4.4. Strategic initiatives
- 8.3.5. Becton
- 8.3.5.1. Company overview
- 8.3.5.2. Financial performance
- 8.3.5.3. Product benchmarking
- 8.3.5.4. Strategic initiatives
- 8.3.6. Dickinson and Company
- 8.3.6.1. Company overview
- 8.3.6.2. Financial performance
- 8.3.6.3. Product benchmarking
- 8.3.6.4. Strategic initiatives
- 8.3.7. TERUMO CORPORATION
- 8.3.7.1. Company overview
- 8.3.7.2. Financial performance
- 8.3.7.3. Product benchmarking
- 8.3.7.4. Strategic initiatives
- 8.3.8. Owen Mumford Ltd.
- 8.3.8.1. Company overview
- 8.3.8.2. Financial performance
- 8.3.8.3. Product benchmarking
- 8.3.8.4. Strategic initiatives
- 8.3.9. Ypsomed
- 8.3.9.1. Company overview
- 8.3.9.2. Financial performance
- 8.3.9.3. Product benchmarking
- 8.3.9.4. Strategic initiatives
- 8.3.10. B. Braun Melsungen AG
- 8.3.10.1. Company overview
- 8.3.10.2. Financial performance
- 8.3.10.3. Product benchmarking
- 8.3.10.4. Strategic initiatives
- 8.3.11. HTL-STREFA
- 8.3.11.1. Company overview
- 8.3.11.2. Financial performance
- 8.3.11.3. Product benchmarking
- 8.3.11.4. Strategic initiatives
- 8.3.12. UltiMed, Inc.
- 8.3.12.1. Company overview
- 8.3.12.2. Financial performance
- 8.3.12.3. Product benchmarking
- 8.3.12.4. Strategic initiatives
- 8.3.13. Allison Medical, Inc.
- 8.3.13.1. Company overview
- 8.3.13.2. Financial performance
- 8.3.13.3. Product benchmarking
- 8.3.13.4. Strategic initiatives
- 8.3.14. Artsana S.P.a
- 8.3.14.1. Company overview
- 8.3.14.2. Financial performance
- 8.3.14.3. Product benchmarking
- 8.3.14.4. Strategic initiative